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Abstract 
Purpose: To carry out a neat synthesis of 2-amino-5,6-dihydro-8-methoxy-4-phenylbenzo[h]quinoline-3-
carbonitrile (compound 2) and 2-amino-5,6-dihydro-8-methoxy-4-phenyl-4H-benzo[h]chromene-3-
carbonitrile (compound 3) and evaluate their cytotoxic activity in human glioblastoma cells. 
Methods: Benzo[h]quinoline and benzo[h]chromene were synthesized by treating 6-methoxy-1-
tetralone with benzylidenemalononitrile under microwave irradiation. The structures of compounds 2 
and 3 were confirmed by elemental, spectral, and x-ray crystallographic analyses. The cytotoxic activity 
of compounds 2 and 3 was evaluated using WST-1 assay in U373 human glioblastoma cell line. 
Results: The molecular structures of compounds 2 and 3 were demonstrated unambiguously from 
single crystal x-ray measurements and they crystallized in triclinic form, P-1, for both compounds. In-
vitro cytotoxic activity data for compound 2 in human glioblastoma cell line (U373) indicate that no 
significant cytotoxicity was observed. On the other hand, compound 3 showed highly significant 
cytotoxic effects on U373 cells at concentrations starting from 0.1 μg/ mL.  
Conclusion: Compound 3 produces a decrease in cell viability with approximately 80 % cell death while 
compound 2 did not indicate significant cytotoxic activity. This suggests that the chromene moiety of 
compound 3 may be responsible for its high cytotoxicity.   
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Literature survey has demonstrated the diversity 
of pharmacological applications of fused 
chromenes such as, anticancer [1,2], 
antibacterial [3], anti-inflammatory [4], 
antioxidants [5,6] and antiprotozoal [7] activities. 
Also, fused quinoline derivatives produce wide 
pharmacological activities such as antibacterial 
[8,9], antifungal [10], antimalarial [11], 
antiplasmodium [12] and anticancer [13,14] 
effects. Moreover, they have been reported to act 
as vesicular glutamate transporters [15] and HIV-
Integrase inhibitors [16]. The combination of 
different ring systems in one compound is one of 
the major tools implemented in this study to 
produce more biologically active products in the 
field of drug development, aiming to obtain more 
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active and less toxic products. Based on the 
above knowledge and in continuation of our 
previous work [17-19], the present study provides 
an evidence for the high efficient biological 
activity of the synthesized benzo[h]quinoline and 





Materials and instruments 
 
Melting points were recorded on a Barnstead 
9001 Electrothermal melting point apparatus and 
are uncorrected. IR spectra were recorded on a 
Perkin Elmer FT-IR Spectrum BX Spectrometer 
at cm-1 scale using KBr discs. 1H-NMR and 13C-
NMR were recorded on a JEOL 500 MHz 
Spectrometer, (Japan) and chemical shift values 
were expressed in δ values (ppm) relative to 
tetramethylsilane (TMS) as an internal standard. 
Coupling constants are given in Hz. The mass 
spectra were recorded on GCMC-QP 1000 EX 
Shimadzo Gas Chromatography MS 
spectrometer, (Japan) E.I. 70 ev. Elemental 
analysis (C, H, N) were carried out at the Micro 
analytical Center, Faculty of Science, Cairo 
University, Egypt, and were in full agreement 
with the proposed structures within ± 0.1-0.2 % 
of the theoretical values. All reagents were of 
analytical grade. The reactions was followed up 
by analytical thin layer chromatography (TLC) on 
pre-coated (0.75 mm) silica gel GF254 plates (E. 
Merck, Germany) and the products were 





In a 5 mL glass tube, to a mixture of 6-methoxy-
1-tetralone (1) (0.176 g, 0.001 mol), 2-
benzylidenemalononitrile (0.154 g, 0.001 mol) in 
ethanol (3 mL), ammonium acetate (0.154 g, 
0.002 mol), few drops of piperidine were added.  
The reaction tube was placed inside the cavity of 
the microwave synthesis system the tube was 
irradiated in the microwave oven with a power of 
400 W, at a temperature of 130 oC, for 15 min. 
After completion of the reaction (monitored by 
TLC) and cooling, the solid formed was filtered 
off, washed with dilute cold ethyl alcohol and 







In a 5 mL glass tube, a mixture of 6-methoxy-1-
tetralone (1) (0.176 g, 0.001 mol), 2-
benzylidenemalononitrile (0.154 g, 0.001 mol) in 
ethanol (3 mL), few drops of piperidine were 
added. The reaction tube was placed inside the 
cavity of the microwave synthesis system, the 
tube was irradiated in the microwave oven with a 
power of 400 W, at a temperature of 130 oC, for 
15 min. After completion of the reaction 
(monitored by TLC) and cooling, the solid formed 
was filtered off, washed with dilute cold ethyl 
alcohol and recrystallized from ethyl alcohol to 
yield compound 3. 
 
X-ray crystallographic analysis 
 
Compounds 2 and 3 were obtained as single 
crystals by slow evaporation from ethanol 
solution of the pure compound at room 
temperature. Data were collected on a Bruker 
APEX-II D8 Venture diffractometer, worked with 
graphite monochromatic Mo Kα radiation at 100 
(2) K. Cell refinement and data reduction were 
carried out by Bruker SAINT. SHELXS-97 [20, 
21] was used to solve the structures. The final 
refinement was carried out by full-matrix least-
squares techniques with anisotropic thermal data 
for nonhydrogen atoms on ܨ. CCDC 140449 and 
1404416 contains the supplementary 
crystallographic data for these compounds and 
can be obtained free of charge from the 





U373 human glioblastoma cell line was used to 
evaluate the cytotoxicity of the compounds. U373 
cells were maintained in DMEM medium 
containing 10 % fetal bovine serum and 1 % 
penicillin/streptomycin. Cells were seeded in 96 
well plates at a density of 5000 cells/well in a 
final volume of 100 μL/well overnight at 37 °C 
and 5 % CO2. Compounds 2 and 3 were 
dissolved in DMSO and 5 different 
concentrations (0.1, 1, 10, 100 and 200 μg/mL) 
were prepared from each compound.  
 
Drugs were added to the cells and the plates 
were incubated for an additional 48 hours at 37 
°C and 5 % CO2. Control cells were incubated 
with DMSO only. Cell viability was assayed using 
WST-1 assay (Clontech) according to the 
manufacturer's protocol. Briefly, 10 µL of 
Premixed WST-1 Cell Proliferation Reagent was 
added to each well after drug incubation for 48 h 
and absorbance was measured 4 h later at 450 
nm using Perkin Elmer Victor 1530 plate reader. 
Each experiment was performed in duplicates, 
and experiments were repeated for each 
concentration 3 or 4 times.  
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Data were analyzed using Prism 5.0 software 
(GraphPad Software, LaJolla, CA, USA). 
Statistical significance was assessed by one-way 
ANOVA test. Data are expressed as mean ± 





Subjecting a mixture of 6-methoxy-1-tetralone 
(1), benzylidenemalononitrile, ammonium acetate 
(in molar ratio 1:1:2, respectively) in ethanol, and 
drops of piperidine as a catalyst, to microwave 
irradiation afforded 2-amino-5,6-dihydro-8-
methoxy-4-phenyl-benzo[h] quinoline-3-
carbonitrile (2) as the isolated product (Scheme 
1).  
 
On the other hand, subjecting a similar amount of 
the mixture 6-methoxy-1-tetralone (1), 
benzylidenemalononitrile in ethanol and drops of 
piperidine to microwave irradiation under the 
same reaction conditions, however in the 
absence of ammonium acetate, furnished the 
respective 2-amino-5,6-dihydro-8-methoxy-4-
phenyl-4H-benzo[h] chromene-3-carbonitrile (3) 
(cf. Scheme 1).  
 
The structures of compounds 2 and 3 were 
confirmed by their elemental, spectral, (IR, 1H 








Yield 80 %; m.p.: 222-224 oC; IR (υmax / cm-1): 
3475, 3379 (NH2), 2208 (CN), 1625 (C=N); 1H-
NMR (CDCl3): δ, 2.6 (m, 2H, CH2), 2.7 (m, 2H, 
CH2), 3.8 (s, 3H, OCH3 ), 5.1  (s, 2H, NH2), 6.7 
(s, 1H, Ar, CH-7), 6.8 (d, J = 8.4 Hz, 1H, Ar-CH-
9), 7.3 (m, 2H, Ar-CH-2`,6`), 7.4-7.5 (m, 3H, Ar-
CH-3`,4`,5`), 8.2 (d, J = 8.4 Hz, 1H, Ar, CH-10); 
13C-NMR (CDCl3): δ, 24.4 (CH2, C-5), 28.1 (CH2, 
C-6), 55.6 (OCH3), 88.09 (C-3), 113.05, 113.22, 
117.53, 117.56, 126.6, 127.9, 128.8, 128.9, 
129.1, 136.6, 141.6, 153.09, 154.6, 159.2, 161.3 
(Ar-C and CN); MS: m/z (%): 327 (M+, 23.9) 
consistent with the molecular formula 
(C21H17N3O). Anal. Calcd. For C21H17N3O 
(327.13): C, 77.04; H, 5.23; N, 12.84. Found: C, 





Yield 85 %; m.p.: 226-228 oC; IR (υmax / cm-1): 
3471, 3392 ( NH2), 2196 (CN), 1695 (C=N); 1H-
NMR (DMSO-d6): δ: 1.79 (m, 1H, CH-5), 2.09 (m, 
1H, CH-5), 2.55 (m, 1H, CH-6), 2.69 (m, 1H, CH-
6), 3.72 (s, 3H, OCH3), 4.00 (s, 1H, CH-4), 6.73 
(s, 1H, Ar-CH-7), 6.77-6.8 (m, 3H, Ar), 7.2-7.3 
(m, 5H, Ar-H and NH2), 7.39 (d, J = 7.8 Hz, 1H, 
Ar-CH-10); 13C-NMR (DMSO-d6): δ, 24.7 (CH2-
5), 27.5 (CH2-6), 42.7 (CH-4), 55.5 (OCH3), 56.8 
(C-3), 109.2, 111.7, 113.9, 121.0, 121.5, 122.4, 
127.4, 128.1, 129.0, 137.6, 140.2, 144.4, 159.6, 
160.3 (Ar-C and CN); MS: m/z (%): 330 (M+, 29) 
consistent with the molecular formula 
(C21H18N2O2). Anal. Calcd. For C21H18N2O2 
(330.13): C, 76.34; H, 5.49; N, 8.48. Found: C, 




Scheme 1: Synthesis of benzo[h]quinoline (2) and benzo[h]chromene (3) 
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For the title compounds, C21H17N3O and 
C21H18N2O2,  the crystallographic data and 
refinement information are summarized in Table 
1. The asymmetric unit of compound 2 contains 
two independent molecules but in case of 
compound 3 it contains only one molecule as 
shown in Figure 1. All the bond lengths and 
angles are in normal ranges [22]. In the crystal 
packing, Figure 2, molecules of compound 2 are 
linked via six intermolecular hydrogen bonds 
(Table 2). Molecules of compound 3 are linked 





U373 human glioblastoma cell line was used for 
in-vitro cytotoxic screening of compounds 2 and 
3, to evaluate their cytotoxicity at 5 different 
concentrations. Results declared that, compound 
2 showed no significant cytotoxic effect on the 
U373 cells (Figure 3). On the contrary, 
compound 3 showed significant cytotoxic effects 
on U373 cells starting at very low concentrations 
(0.1 μg/mL). Moreover, the highest concentration 
used in this study (200 μg/mL) led to a highly 
significant effect, decreasing cell viability to 20 % 
and causing approximately 80 % cell death 
(Figure 4). 
 
Compound 2 Compound 3 
 
 
Figure 1: ORTEP diagrams of the titled compounds. Displacement ellipsoids are plotted at 40 % probability level 
for non-H atoms 
 
   
Figure 2: Molecular packing of titled compounds viewed approximately three dimensional networks hydrogen 
bonds are drawn as dashed lines 
 
Compound 3 Compound 2 
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Table 1: X-ray experimental data for compounds 2 and 3 
 
Crystal data  Compound 2 Compound 3 
Chemical formula C21H17N3O C21H18N2O2 
Molecular weight 327.38 330.37 
Crystal system, space group Triclinic, P-1 Triclinic, P-1 
Temperature (K) 100 100 
a, b, c (Å) 10.3257 (4), 11.3877 (4), 14.5723 (5) 5.8471 (2), 10.7343 (4), 13.7601 (6) 
α, β, γ (°) 94.304 (1), 108.719 (1), 93.150 (1) 103.191 (1), 97.519 (1), 102.448 (1) 
V (Å3) 1612.61 (10) 806.23 (5) 
Z 4 2 
Radiation  type Mo Kα Mo Kα 
µ (mm−1) 0.09 0.09 
Crystal size (mm) 0.60 × 0.52 × 0.14 0.57 × 0.21 × 0.16 
Data collection 
Diffractometer Bruker APEX-II D8 Venture  Bruker APEX-II D8 Venture  
Absorption correction Multi-scan  
SADABS Bruker 2014 
Multi-scan  
SADABS Bruker 2014 
Tmin, Tmax 0.951, 0.988 0.951, 0.988 
No. of measured, independent and 
observed [I > 2σ (I)] reflections 82401, 12334, 10356 45149, 6163, 4595 
Rint 0.048 0.056 
Refinement 
R[F2 > 2σ( F2)], wR ( F2), S 0.045, 0.126, 1.05 0.048, 0.126, 1.05 
No. of reflections 12334 6163 
No. of parameters 469 235 
No. of restraints 0 0 
Δρmax, Δρmin (e Å−3) 0.53, −0.25 0.41, −0.28 
 
Table 2: Hydrogen-bond geometry (Å, °) for compounds 2 and 3 
 
Compound 2 
D—H···A D—H H···A D···A D—H···A 
N3A—H1A···N2Bi 0.878 (17) 2.261 (17) 3.0169 (12) 144.2 (16) 
N3B—H1B···N2Aii 0.878 (17) 2.273 (16) 3.0232 (12) 143.5 (14) 
N3A—H2A···O1Biii 0.889 (17) 2.426 (18) 3.2212 (12) 149.1 (14) 
N3B—H2B···O1Aiv 0.874 (17) 2.293 (17) 3.1212 (12) 158.3 (14) 
C15B—H15B···O1Av 0.9300 2.5900 3.2959 (12) 133.00 
C18A—H18A···N1Bvi 0.9300 2.5900 3.4680 (12) 157.00 
Symmetry codes: (i) x, y−1, z−1; (ii) x, y+1, z+1; (iii) x, y−1, z; (iv) x, y+1, z; (v) −x+1, −y+1, −z+1; (vi) −x+1, −y+2, 
−z. 
Compound 3 
D—H···A D—H H···A D···A D—H···A 
N2—H2N2···N1i 0.895 (18) 2.141 (18) 3.0235 (16) 168.6 (16) 
C15—H15A···N1ii 0.9500 2.5500 3.4266 (16) 154.00 
Symmetry codes: (i) −x−1, −y+1, −z+1; (ii) x+1, y, z. 
  
 
Figure 3: Effect of compound 2 on U373 cell survival. 
U373 cells were incubated for 48 h with 0.1, 1, 10, 100 
or 200 μg/mL for compound 2. Cell viability was 
determined by WST-1 assay. Data expressed as 
mean ± S.E.M (n = 3 or 4) 
  
Figure 4: Effect of compound 3 on U373 cell survival. 
U373 cells were incubated for 48 h with 0.1, 1, 10, 100 
or 200 μg/mL of compound 3. Cell viability was 
determined by WST-1 assay. Data expressed as 
mean ± SEM (n = 3 or 4); ** p < 0.01, *** p < 0.001 vs. 
control untreated cells, one-way ANOVA 
Haiba et al 




The structures of benzo[h] quinoline-3-
carbonitrile 2 and benzo[h]chromene-3-
carbonitrile 3 have been established by x-ray 
crystallography and supported by spectral data. 
Mass spectra revealed a [M]+ ion peaks at 327 
and 330 assignable to the molecular weight of 
compounds 2 and 3, respectively. In 1H NMR 
spectra characteristic signals resonating at δ = 
5.1 ppm (for compound 2) and δ = 7.2-7.3 ppm 
(for compound 3) were typical for NH2 groups. IR 
showed absorption bands at 3475-3471, 3379-
3392 (NH2), 2208, 2196 (CN) cm-1. 
 
The anticancer activity results declared that 
compound 2 showed no significant cytotoxic 
effect on the U373 cells. Higher concentrations 
starting at 100 μg/mL demonstrated a slight non-
significant decrease in cell viability compared to 
the controls (untreated cells). Incubating the 
U373 cells with 100 μg/mL of compound 2 for 48 
h decreased cell viability to approximately 72 % 
compared to the control (Figure 3), however, this 
effect was not statistically significant. On the 
other hand, compound 3 demonstrated high 
cytotoxic effects towards U373 human 
glioblastoma cell line. Incubation of U373 cells 
with 0.1 μg/mL of compound 3 decreased cell 
viability significantly to approximately 55 %, 
surprisingly increasing concentrations ranging 
from 1-10 μg/mL had a mild non-significant effect 
on cell viability (approximately 80 %). A 
remarkable cytotoxic effect was seen again at 
100 μg/mL decreasing viability significantly to 45 
%, and 200 μg/mL of compound 3 decreased cell 
viability by up to 20 %, meaning it led to 




The present study provides a simple and rapid 
method for synthesizing benzo[h]quinoline 2 and 
benzo[h]chromene 3. The chromene moiety of 
compound 3 may be responsible for the high 
cytotoxicity, thus underlining the importance of 
the development of chromene derivatives in 
future work, with the aim to synthesize more 
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